Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Apr;38(4):837–841. doi: 10.1128/aac.38.4.837

Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously.

M Dan 1, F Poch 1, C Quassem 1, R Kitzes 1
PMCID: PMC284551  PMID: 8031055

Abstract

The pharmacokinetics and serum bactericidal activities of three intravenous doses of ciprofloxacin were studied comparatively in 30 patients. Single 200-, 300-, and 400-mg intravenous doses of ciprofloxacin were given over 30 min to 10 patients each, and serum samples were obtained at 0.5, 1, 2, 3, 4, 8, and 12 h after the start of the infusion. Serum drug concentrations were determined by high-pressure liquid chromatography. Pharmacokinetic parameters were estimated by using noncompartmental analysis methods. Serum bactericidal activity against clinical isolates of Escherichia coli, Enterobacter cloacae, Pseudomonas aeruginosa, Acinetobacter calcoaceticus, and Staphylococcus aureus was determined for samples obtained at 0.5, 4, 8, and 12 h. Excellent activity was demonstrated up to 12 h by all doses against E. coli and E. cloacae. Much poorer titers were observed for the remaining organisms, although the 400-mg dose prompted improved results against P. aeruginosa with a mean bactericidal titer of 1:2.9 at 8 h. In conclusion, while the 200-mg dose appears to be largely adequate for infections caused by members of the family Enterobacteriaceae, it seems that when P. aeruginosa is involved, 400 mg twice a day or even three times a day is more appropriate. Intravenous ciprofloxacin performs poorly against A. calcoaceticus and S. aureus, even at a higher dose.

Full text

PDF
837

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boeckh M., Lode H., Deppermann K. M., Grineisen S., Shokry F., Held R., Wernicke K., Koeppe P., Wagner J., Krasemann C. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother. 1990 Dec;34(12):2407–2414. doi: 10.1128/aac.34.12.2407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Braveny I., Machka K., Milatovic D. Evaluation of novel antipseudomonal drugs using the serum bactericidal activity test. Eur J Clin Microbiol. 1986 Feb;5(1):119–123. doi: 10.1007/BF02013481. [DOI] [PubMed] [Google Scholar]
  3. Brittain D. C., Scully B. E., McElrath M. J., Steinman R., Labthavikul P., Neu H. C. The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. J Clin Pharmacol. 1985 Mar;25(2):82–88. doi: 10.1002/j.1552-4604.1985.tb02806.x. [DOI] [PubMed] [Google Scholar]
  4. Campoli-Richards D. M., Monk J. P., Price A., Benfield P., Todd P. A., Ward A. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1988 Apr;35(4):373–447. doi: 10.2165/00003495-198835040-00003. [DOI] [PubMed] [Google Scholar]
  5. Coleman D. L., Horwitz R. I., Andriole V. T. Association between serum inhibitory and bactericidal concentrations and therapeutic outcome in bacterial endocarditis. Am J Med. 1982 Aug;73(2):260–267. doi: 10.1016/0002-9343(82)90188-7. [DOI] [PubMed] [Google Scholar]
  6. Cooper B., Lawlor M. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med. 1989 Oct;87(4):475–475. doi: 10.1016/s0002-9343(89)80838-1. [DOI] [PubMed] [Google Scholar]
  7. Drake T. A., Hackbarth C. J., Sande M. A. Value of serum tests in combined drug therapy of endocarditis. Antimicrob Agents Chemother. 1983 Nov;24(5):653–657. doi: 10.1128/aac.24.5.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Drusano G. L., Johnson D. E., Rosen M., Standiford H. C. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993 Mar;37(3):483–490. doi: 10.1128/aac.37.3.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Eliopoulos G. M., Gardella A., Moellering R. C., Jr In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother. 1984 Mar;25(3):331–335. doi: 10.1128/aac.25.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fabre D., Bressolle F., Gomeni R., Arich C., Lemesle F., Beziau H., Galtier M. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother. 1991 Dec;35(12):2521–2525. doi: 10.1128/aac.35.12.2521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Forrest A., Nix D. E., Ballow C. H., Goss T. F., Birmingham M. C., Schentag J. J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993 May;37(5):1073–1081. doi: 10.1128/aac.37.5.1073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Israel D., Gillum J. G., Turik M., Harvey K., Ford J., Dalton H., Towle M., Echols R., Heller A. H., Polk R. Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1993 Oct;37(10):2193–2199. doi: 10.1128/aac.37.10.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lagast H., Husson M., Klastersky J. Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis. J Antimicrob Chemother. 1985 Sep;16(3):341–347. doi: 10.1093/jac/16.3.341. [DOI] [PubMed] [Google Scholar]
  14. Lettieri J. T., Rogge M. C., Kaiser L., Echols R. M., Heller A. H. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992 May;36(5):993–996. doi: 10.1128/aac.36.5.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Paradis D., Vallée F., Allard S., Bisson C., Daviau N., Drapeau C., Auger F., LeBel M. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother. 1992 Oct;36(10):2085–2092. doi: 10.1128/aac.36.10.2085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Peloquin C. A., Cumbo T. J., Nix D. E., Sands M. F., Schentag J. J. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med. 1989 Oct;149(10):2269–2273. [PubMed] [Google Scholar]
  17. Schentag J. J. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scand J Infect Dis Suppl. 1990;74:218–234. [PubMed] [Google Scholar]
  18. Sculier J. P., Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. doi: 10.1016/0002-9343(84)90662-4. [DOI] [PubMed] [Google Scholar]
  19. Standiford H. C., Drusano G. L., Forrest A., Tatem B., Plaisance K. Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers. Antimicrob Agents Chemother. 1987 Aug;31(8):1177–1182. doi: 10.1128/aac.31.8.1177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Standiford H. C., Tatem B. A. Technical aspects and clinical correlations of the serum bactericidal test. Eur J Clin Microbiol. 1986 Feb;5(1):79–87. doi: 10.1007/BF02013474. [DOI] [PubMed] [Google Scholar]
  21. Stratton C. W., Weinstein M. P., Reller L. B. Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration. J Infect Dis. 1982 Feb;145(2):160–168. doi: 10.1093/infdis/145.2.160. [DOI] [PubMed] [Google Scholar]
  22. Van der Auwera P., Klastersky J. Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin. Antimicrob Agents Chemother. 1986 Dec;30(6):892–895. doi: 10.1128/aac.30.6.892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Weinstein M. P., Stratton C. W., Ackley A., Hawley H. B., Robinson P. A., Fisher B. D., Alcid D. V., Stephens D. S., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985 Feb;78(2):262–269. doi: 10.1016/0002-9343(85)90436-x. [DOI] [PubMed] [Google Scholar]
  24. Wolfson J. S., Swartz M. N. Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med. 1985 Apr 11;312(15):968–975. doi: 10.1056/NEJM198504113121507. [DOI] [PubMed] [Google Scholar]
  25. Zeiler H. J., Beermann D., Wingender W., Förster D., Schacht P. Bactericidal activity of ciprofloxacin, norfloxacin and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection. 1988;16 (Suppl 1):S19–S23. doi: 10.1007/BF01650502. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES